80
Participants
Start Date
February 23, 2023
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
Nicotinamide Riboside
"Investigators will use (Good Manufacturing Process) GMP-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA).~NR is distributed by ChromaDex, Inc., Irvine, CA. NR is available as 300 mg capsules.~The dietary supplement will be re-labeled by the Hospital of the University of Pennsylvania (HUP) Investigational Drug Service according to FDA regulations, including subject and physician name and NR or Placebo 300 mg capsules."
Placebo
The matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule)
Exercise Intervention
The exercise program consists of at-home training sessions and will include aerobic and strengthening components designed to progress persons gradually to 150-300 minutes of the equivalent of moderate aerobic activity, and twice weekly strengthening over 16 weeks. For aerobic training, the eventual intensity and duration goal (adapted for each person as necessary) will be for persons to train at 70-80% of peak 2MSPT heart rate 20-45 minutes 3-5 days/week. For resistance exercises the goal will be a load/weight that results in fatigue after 3 sets of 10-12 repetitions on 8-10 exercises 2 days/week.
RECRUITING
Children's Hospital of Philadelphia, Philadelphia
RECRUITING
St. Jude Children's Research Hospital, Memphis
RECRUITING
City of Hope Medical Center, Duarte
National Institutes of Health (NIH)
NIH
City of Hope Medical Center
OTHER
St. Jude Children's Research Hospital
OTHER
National Cancer Institute (NCI)
NIH
University of Pennsylvania
OTHER
Children's Hospital of Philadelphia
OTHER